Uptick in ECL labels for pharma industry

US label systems provider Luminer is seeing a significant rise in demand for extended content labels (ECLs) for clinical trials, several of which deal with ongoing development of drugs related to the coronavirus pandemic.

Another pharma niche seeing a spike in orders are labels for over-the-counter medications that mitigate flu-like symptoms.

A number of these products, especially those in small packaging, require multi-page labels to meet regulatory requirements. The sudden prioritisation of drugs to combat coronavirus symptoms, as well as the search for an effective vaccine, has led to some labelling formats being particularly sought-after.

Extended content labels are in especially high demand for multi-language instructions.

Tom Spina, President and CEO of Luminer, expects growth to continue into the summer.

Image credits: www.luminer.com